Patents Assigned to ALECTOR LLC
-
Patent number: 12753225Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 1, 2023Date of Patent: October 6, 2026Assignee: Alector LLCInventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
-
Patent number: 12723077Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.Type: GrantFiled: February 17, 2021Date of Patent: September 1, 2026Assignee: Alector LLCInventors: Spencer Liang, Samuel Nalle, Ling Leung
-
Publication number: 20260209350Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: September 12, 2025Publication date: July 23, 2026Applicant: Alector LLCInventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
-
Publication number: 20260126446Abstract: The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and/or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and/or Siglec-9, and in some embodiments also CD68 and/or sialic acid expression in tumor or immune cells.Type: ApplicationFiled: November 6, 2023Publication date: May 7, 2026Applicant: Alector LLCInventors: Samuel Nalle, Spencer Liang
-
Publication number: 20260070976Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PIL-RA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or anti-gen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.Type: ApplicationFiled: February 29, 2024Publication date: March 12, 2026Applicant: Alector LLCInventors: Samuel Nalle, Ling Leung, Yong Wang, Angie Grace Yee
-
Publication number: 20250333523Abstract: The present disclosure is generally directed to compositions that include monovalent antibodies, e.g., monoclonal monovalent antibodies that specifically bind a IL18BP polypeptide, e.g., a mammalian IL18BP polypeptide or human IL18BP polypeptide, and use of such compositions in treating an individual in need thereof.Type: ApplicationFiled: July 3, 2025Publication date: October 30, 2025Applicant: Alector LLCInventors: Farah Riad Itani, Angie Grace Yee, Yong Wang, Wei Li, Wei-Hsien Ho, Marina Roell, Seung-Joo Lee, Spencer Liang, Li Zhou, Belvin Gong
-
Publication number: 20250297016Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 9, 2025Publication date: September 25, 2025Applicant: Alector LLCInventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
-
Publication number: 20250270319Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 6, 2025Publication date: August 28, 2025Applicant: Alector LLCInventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
-
Patent number: 12358991Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: June 9, 2022Date of Patent: July 15, 2025Assignee: Alector LLCInventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
-
Publication number: 20250223365Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.Type: ApplicationFiled: July 18, 2024Publication date: July 10, 2025Applicant: Alector LLCInventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
-
Patent number: 12331111Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 19, 2022Date of Patent: June 17, 2025Assignee: Alector LLCInventors: Philip Kong, Herve Rhinn, Tina Schwabe, Angie Yee, Ilaria Tassi, Muhammad Abbas Alhawagri, Arnon Rosenthal
-
Patent number: 12331112Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 19, 2022Date of Patent: June 17, 2025Assignee: Alector LLCInventors: Philip Kong, Herve Rhinn, Tina Schwabe, Angie Yee, Ilaria Tassi, Muhammad Abbas Alhawagri, Arnon Rosenthal
-
Publication number: 20250179189Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 19, 2025Publication date: June 5, 2025Applicant: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Patent number: 12319734Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 18, 2022Date of Patent: June 3, 2025Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Eric Brown, Tina Schwabe, Angie Yee, Herve Rhinn
-
Patent number: 12297277Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: June 9, 2022Date of Patent: May 13, 2025Assignee: Alector LLCInventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
-
Publication number: 20250144209Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.Type: ApplicationFiled: January 9, 2025Publication date: May 8, 2025Applicant: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
-
Publication number: 20250145709Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: January 9, 2025Publication date: May 8, 2025Applicant: Alector LLCInventors: Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
-
Patent number: 12258398Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: July 26, 2019Date of Patent: March 25, 2025Assignee: ALECTOR LLCInventors: Patricia Culp, Rashmi Bankoti, Helen Lam, Arnon Rosenthal
-
Publication number: 20250092144Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: November 22, 2024Publication date: March 20, 2025Applicant: Alector LLCInventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
-
Publication number: 20250092131Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: September 4, 2024Publication date: March 20, 2025Applicant: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
